Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab

  1. Adrián Sánchez-Montalvá
  2. Júlia Sellarés-Nadal
  3. Juan Espinosa-Pereiro
  4. Nuria Fernández-Hidalgo
  5. Santiago Pérez-Hoyos
  6. Fernando Salvador
  7. Xavier Durà
  8. Marta Miarons
  9. Andrés Antón
  10. Simeón Eremiev-Eremiev
  11. Abiu Sempere-González
  12. Arnau Monforte-Pallarés
  13. Pau Bosch-Nicolau
  14. Salvador Augustin
  15. Júlia Sampol
  16. Alfredo Guillén-del-Castillo
  17. Benito Almirante

Reviewed by

Read the full article

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.medcli.2021.06.012
  2. ScreenIT

    SciScore for 10.1101/2020.05.07.20094599: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Data sources: Data were collected retrospectively from the medical charts of tpatients from the 13th of March, 2020 to the 18th of March, 2020, when the protocol was submitted to the institutional review board, and prospectively thereafter.
    Consent: Patients were asked for an oral consent.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    19,20 Data was recorded in the Research Electronic Data Capture software (REDCap, Vanderbilt University).
    REDCap
    suggested: (REDCap, RRID:SCR_003445)
    Analysis was performed with Stata 15.1 software (StataCorp).
    StataCorp
    suggested: (Stata, RRID:SCR_012763)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This preliminary exploratory study has several limitations. First, there is no control group and the minimum follow up period was 7 days. Therefore, at this point it is not possible to evaluate the differences between patients receiving tocilizumab or not and, consequently, it is not possible to evaluate solidly what is the overall benefit of administering this drug. However, the urgency of obtaining data on new therapies justifies the early communication of these results. Second, ICU admission is not a very robust endpoint since it depends on the attitudes of the treating physicians as well as the availability of beds at times of resource scarcity and overwhelming demand. For this reason, mortality was selected as the main outcome in our study. Besides, the subsequent analysis of all patients included in the Vall d’Hebron COVID-19 Prospective Cohort Study may solve this limitation and inform results with a longer follow up period. Finally, our data is limited to a single centre. While our results may not be extrapolated to other populations or other standards of care, the management of patients was homogeneous avoiding the centre effect of multicentric studies. Multivariate analysis is limited by sample size.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.05.07.20094599 on medRxiv